June 2023 Neurology Recall: Biomarker Discovery in Parkinson Disease
Neurology® Podcast
00:00
The Impact of the Study on Parkinson's Disease
The study will be a very useful research tool for identifying people that have typical snooplion pathology who would be the best candidates participate in trials testing anti-sneuclein aggregation therapies for Parkinson's disease. The results are not going to affect our on the ground clinical treatment decisions levodopa is still going to be a primary symptomatic therapy that we're going to use but now stepping into your role as a movement disorders clinician can you tell us how the information and the knowledge gained from this study is affecting the conversations you have with your patients?
Transcript
Play full episode
